Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.54 |
| ▸ | RXRA | P19793 | 7/20 | 0.50 |
| ▸ | RXRB | P28702 | 7/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | RXRG | P48443 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883010 | 0.88 | PTGDR2 (0.60) | PTGDR2TUBB1 | |
| SCHEMBL5943423 | 0.86 | TUBB1 (0.64) | RXRARXRBNR4A2NPC1RAB9A | |
| SCHEMBL7285781 | 0.84 | PTGDR2 (0.69) | PTGDR2RAB9APOLBTSHRTUBB1 | |
| SCHEMBL6700077 | 0.82 | ERN1 (0.56) | RXRARXRBNR4A2NPC1RAB9A | |
| SCHEMBL930474 | 0.80 | MRGPRX4 (0.55) | RXRARXRBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29958502 | 0.80 | NR4A2 (0.56) | RXRARXRBNR4A2NPC1RAB9A | |
| SCHEMBL6700704 | 0.80 | RXRA (0.48) | RXRARXRBNR4A2NPC1RAB9A | |
| SCHEMBL5883150 | 0.79 | PTGDR2 (0.62) | PTGDR2RAB9APOLBTSHRTUBB1 | |
| SCHEMBL6693981 | 0.79 | RAB9A (0.56) | NPC1RAB9ASMN1; SMN2POLBTUBB1 | |
| SCHEMBL29955503 | 0.78 | PTGDR2 (0.62) | PTGDR2RXRARXRBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063647-A1 | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-6649172-B2 | 5-(p-carboxybenzyloxy)-2-oxybenzaldehyde derivatives; vaccine adjuvants | CORIXA CORPORATION | 2003-11-18 | — | — | US | disclosed |
| EP-1265840-A2 | NOVEL AMPHIPATHIC ALDEHYDES AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20010053363-A1 | Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors | CORIXA CORPORATION | 2001-12-20 | — | — | US | disclosed |
| WO-2001070663-A2 | NOVEL AMPHIPATHIC ALDEHYDES AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063647-A1 | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors | MAVS, TLR3, LY96 | PTGDR2 2223/4885RXRA 333/4885RXRB 291/4885 |
| US-20010053363-A1 | Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors | MAVS, TLR3, LY96 | PTGDR2 2143/4885RXRA 344/4885RXRB 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.